Search

Your search keyword '"P., Di Leo"' showing total 22 results
Start Over Author "P., Di Leo" Journal journal of clinical oncology
22 results on '"P., Di Leo"'

1. Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Update.

Author

Moy, Beverly, Rumble, R Bryan, Come, Steven E, Davidson, Nancy E, Di Leo, Angelo, Gralow, Julie R, Hortobagyi, Gabriel N, Yee, Douglas, Smith, Ian E, Chavez-MacGregor, Mariana, Nanda, Rita, McArthur, Heather L, Spring, Laura, Reeder-Hayes, Katherine E, Ruddy, Kathryn J, Unger, Paul S, Vinayak, Shaveta, Irvin, William J Jr, Armaghani, Avan, and Danso, Michael A

Published
2021
Full Text
View/download PDF

3. Absolute Improvements in Freedom From Distant Recurrence to Tailor Adjuvant Endocrine Therapies for Premenopausal Women: Results From TEXT and SOFT.

Author

Pagani, Olivia, Francis, Prudence A., Fleming, Gini F., Walley, Barbara A., Viale, Giuseppe, Colleoni, Marco, Láng, István, Gómez, Henry L., Tondini, Carlo, Pinotti, Graziella, Di Leo, Angelo, Coates, Alan S., Goldhirsch, Aron, Gelber, Richard D., Regan, Meredith M., and SOFT and TEXT Investigators and International Breast Cancer Study Group

Published
2020
Full Text
View/download PDF

4. Neoadjuvant Degarelix Versus Triptorelin in Premenopausal Patients Who Receive Letrozole for Locally Advanced Endocrine-Responsive Breast Cancer: A Randomized Phase II Trial.

Author

Dellapasqua, Silvia, Gray, Kathryn P., Munzone, Elisabetta, Rubino, Daniela, Gianni, Lorenzo, Johansson, Harriet, Viale, Giuseppe, Ribi, Karin, Bernhard, Jürg, Kammler, Roswitha, Maibach, Rudolf, Rabaglio-Poretti, Manuela, Ruepp, Barbara, Di Leo, Angelo, Coates, Alan S., Gelber, Richard D., Regan, Meredith M., Goldhirsch, Aron, Colleoni, Marco, and International Breast Cancer Study Group

Published
2019
Full Text
View/download PDF

5. MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.

Author

Goetz, Matthew P., Masakazu Toi, Campone, Mario, Joohyuk Sohn, Paluch-Shimon, Shani, Huober, Jens, In Hae Park, Trédan, Olivier, Shin-Cheh Chen, Luis Manso, Freedman, Orit C., Jaliffe, Georgina Garnica, Forrester, Tammy, Frenzel, Martin, Barriga, Susana, Smith, Ian C., Bourayou, Nawel, Di Leo, Angelo, Toi, Masakazu, and Sohn, Joohyuk

Published
2017
Full Text
View/download PDF

6. Estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor expression and benefit from lapatinib in a randomized trial of paclitaxel with lapatinib or placebo as first-line treatment...

Author

Finn RS, Press MF, Dering J, Arbushites M, Koehler M, Oliva C, Williams LS, Di Leo A, Finn, Richard S, Press, Michael F, Dering, Judy, Arbushites, Michael, Koehler, Maria, Oliva, Cristina, Williams, Lisa S, and Di Leo, Angelo

Published
2009
Full Text
View/download PDF

9. Predicting Anthracycline Benefit: TOP2A and CEP17-Not Only but Also.

Author

Bartlett, John M S, McConkey, Christopher C, Munro, Alison F, Desmedt, Christine, Dunn, Janet A, Larsimont, Denis P, O'Malley, Frances P, Cameron, David A, Earl, Helena M, Poole, Christopher J, Shepherd, Lois E, Cardoso, Fatima, Jensen, Maj-Britt, Caldas, Carlos, Twelves, Christopher J, Rea, Daniel W, Ejlertsen, Bent, Di Leo, Angelo, and Pritchard, Kathleen I

Published
2015
Full Text
View/download PDF

10. Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31.

Author

Gelmon, Karen A., Boyle, Frances M., Kaufman, Bella, Huntsman, David G., Manikhas, Alexey, Di Leo, Angelo, Martin, Miguel, Schwartzberg, Lee S., Lemieux, Julie, Aparicio, Samuel, Shepherd, Lois E., Dent, Susan, Ellard, Susan L., Tonkin, Katia, Pritchard, Kathleen I., Whelan, Timothy J., Nomikos, Dora, Nusch, Arnd, Coleman, Robert E., and Mukai, Hirofumi

Published
2015
Full Text
View/download PDF

11. The role of reduced glutathione on oxaliplatin-induced neuropathy in colorectal cancer patients

Author

N. Calvi, G. Lelli, C. Romano, P. Di Leo, A. Capobianco, Mariarosa Coccaro, Gianpiero Romano, Annamaria Bochicchio, Raffaele Ardito, Vito Lorusso, and Alfredo Tartarone

Subjects
Oncology, Cancer Research, medicine.medical_specialty, Chemotherapy, business.industry, Colorectal cancer, medicine.medical_treatment, Glutathione, medicine.disease, Oxaliplatin, stomatognathic diseases, chemistry.chemical_compound, Sensory ataxia, chemistry, Internal medicine, medicine, Peripheral sensory neuropathy, medicine.symptom, business, medicine.drug
Abstract

19539 Background: Peripheral sensory neuropathy is a common side-effect of oxaliplatin based chemotherapy. The neuropathy is cumulative and dose-related. Symptoms include sensory ataxia and dysesthesia of the limbs, mouth, throat and larynx, and may be exacerbated by exposure to cold. Studies suggest that Glutathione (GSH) is neuroprotective against oxaliplatin-induced neuropathy. Methods: From Jan. 2004, 83 consecutive colorectal cancer patients (pts) elegibile to oxaliplatin-based regimen were treated with GSH 1500 mg/mq over a 15-minute infusion period before oxaliplatin. Treatment-related toxicity was evaluated based on National Cancer Institute (NCI) Criteria. Results: After four cycles of chemotherapy, 5 pts (6%) experienced G1 neurotoxicity. After eight cycles, 2 pts (2.4%) experienced G2 sensory neuropathy (duration < 7 days) and 8 (9.6%) pts G1. After 12 cycles, G3 sensory neuropathy was observed in 2 pts (2.4%), G2 in 8 (9.6%) and G1 in 11 pts (13%). Neither G4 sensory neuropathy was registered nor treatment interruption was required. Conclusions: These findings suggest that use of GSH may protect from oxaliplatin-induced neuropathy. In fact, in our series, only 2 (2.4%) pts experienced severe paresthesia interfering with daily activities and none hade permanent sensory loss. However, only a well designed randomised controlled study will definitely prove the protective effect of GSH on oxaliplatin induced neurotoxicity. No significant financial relationships to disclose.

Published
2007
Full Text
View/download PDF

12. Protracted infusion of 5 fluorouracil and toxicity during CMF administration in adjuvant setting of breast cancer

Author

Raffaele Ardito, P. Di Leo, Annamaria Bochicchio, Mariarosa Coccaro, A. Capobianco, A. Capoblanco, C. Romano, and Alfredo Tartarone

Subjects
Drug, Cancer Research, business.industry, medicine.medical_treatment, media_common.quotation_subject, Pharmacology, medicine.disease, Breast cancer, Oncology, Mechanism of action, Fluorouracil, Toxicity, medicine, medicine.symptom, business, Adjuvant, Administration (government), medicine.drug, media_common
Abstract

19618 Background: Protracted infusion of 5FU(PI) increases response rates and reduces toxicity when compared to bolus administration (BA): the mechanism of action of this drug appears to depend on the dose and the schedule of administration. In some trials 5FU was given as a BA: 30% incidence of severe mucositis or diarrhea was observed. These side effect decreased to less than 15% in trials in which 5FU was infused over 30 minutes and even less when the same dose of 5FU was given over 1 hour or over 2 hours. The CMF i.v. schedule with BA of all three drugs in the adjuvant setting of breast cancer has been shown to be associated with frequent gastrointestinal and mielo-toxicity. PI of 5FU in the CMF schedule can reduce toxicity and improve the quality of life. Methods and Results: From July 2003 to October 2006, 95 patients with breast cancer, mean age 56 years (range 40–75) were treated with adjuvant CMF (1, 8 every 28 days) with 5FU PI (1 hour). Toxicity and compliance were compared to those of 75 patients treated in our institution with CMF-5FU BA (10 min). Toxicity was coded by NCI-CTC. We observed that the patients treated with CMF-5FU PI compared to 5FU BA showed G2–3 nausea: 31.5% vs 46%, G2–3 emesis: 26.3% vs 34.6%, G2 diarrhea: 0% vs 2.6%,asthenia: 18.9% vs 33.3%, G2 neutropenia: 21.0% vs 30.6%, G3 neutropenia: 18.9% vs 20.0% ,G4 neutropenia: 9.4% vs 12%,G3–4 mucositis: 12.6% vs 18.6% and hand -foot syndrome 1.0% vs 0%. Compliance in CMF with 5FU PI compared to CMF with 5FU BA was: 6 cycles administered in 92.6% vs 88.0%, day 8 omitted in 11.5% vs 13.3%, dose reduction in 15.7% vs 17.3%. Conclusions: In our experience, 5 FU PI reduces the gastrointestinal toxicity, particularly nausea and emesis compared to BA.We suggest that less toxicity treatment schedule improves the quality of life and is mandatory mainly in frail and elderly patients. No significant financial relationships to disclose.

Published
2007
Full Text
View/download PDF

13. Prevention of high dose melphalan-induced mucositis by cryotherapy in transplanted patients

Author

P. Di Leo, Giovanni Iodice, Annamaria Bochicchio, Mariarosa Coccaro, Gianpiero Romano, A. Capobianco, R. Matera, G. Lelli, N. Di Renzo, and Alfredo Tartarone

Subjects
Melphalan, Cancer Research, medicine.medical_specialty, business.industry, medicine.medical_treatment, Cryotherapy, macromolecular substances, medicine.disease, Gastroenterology, Lymphoma, Surgery, Transplantation, stomatognathic diseases, Breast cancer, stomatognathic system, Oncology, Internal medicine, medicine, Mucositis, Ovarian cancer, business, Multiple myeloma, medicine.drug
Abstract

8174 Background: Oral mucositis is a severe problem for patients (pts) undergoing high dose chemotherapy (HDC) followed by peripheral blood progenitor cells transplantation. Once mucositis has occurred, treatment consists of measures to palliate symptoms. Multiple agents have been used prophylactically to reduce this toxicity with discordant results. Oral cryotherapy, through vasoconstriction, can decrease the mucosal damage induced by agents with short half-lives, such as melphalan (L-PAM). Aim of this study was to evaluate the effect of local cryotherapy on oral mucositis in pts treated with high-dose (HD) L-PAM Methods: From December 2001, 23 pts (5 with multiple myeloma, 9 with non Hodgkin's Lymphoma, 7 with breast cancer, 1 with ovarian cancer) underwent HDC including L-PAM; in particular, 5 pts received HD L-PAM (140–160 mg/m2) alone and 17 pts a L-PAM including conditioning regimen. All these pts were asked to suck on ice chips for 30 minutes, starting 5 minutes prior to the L-PAM infusion. These p...

Published
2004
Full Text
View/download PDF

15. Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98.

Author

Loi, Sherene, Sirtaine, Nicolas, Piette, Fanny, Salgado, Roberto, Viale, Giuseppe, Van Eenoo, Françoise, Rouas, Ghizlane, Francis, Prudence, Crown, John P A, Hitre, Erika, de Azambuja, Evandro, Quinaux, Emmanuel, Di Leo, Angelo, Michiels, Stefan, Piccart, Martine J, and Sotiriou, Christos

Published
2013
Full Text
View/download PDF

16. Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to DoxorubicinWith Doxorubicin-Based Chemotherapy: BIG 02-98.

Author

Loi, Sherene, Sirtaine, Nicolas, Piette, Fanny, Salgado, Roberto, Viale, Giuseppe, Van Eenoo, Françoise, Rouas, Ghizlane, Francis, Prudence, Crown, John P. A., Hitre, Erika, de Azambuja, Evandro, Quinaux, Emmanuel, Di Leo, Angelo, Michiels, Stefan, Piccart, Martine J., and Sotiriou, Christos

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results